Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HealthCare Global Enterprises Buyback Yield % Chart
NSE:HCG vs HCA, THC, DVA: Buyback Yield % Comparison
For the Medical Care Facilities subindustry, HealthCare Global Enterprises's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HealthCare Global Enterprises Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HealthCare Global Enterprises's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where HealthCare Global Enterprises's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HealthCare Global Enterprises (NSE:HCG) has a Buyback Yield % of -4.51 as of Jul. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on HealthCare Global Enterprises and its competitors. According to the industry distribution chart, HealthCare Global Enterprises ranks #193 out of 274 companies in the Healthcare Providers & Services industry, placing it in the top 70.4%.
Is HealthCare Global Enterprises' Buyback Yield % too high?
HealthCare Global Enterprises' current Buyback Yield % is -4.51. Based on the distribution chart, HealthCare Global Enterprises ranks #193 out of 274 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, HealthCare Global Enterprises has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HealthCare Global Enterprises' Buyback Yield % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, HealthCare Global Enterprises ranks #193 out of 274 companies for Buyback Yield %. This places HealthCare Global Enterprises in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on HealthCare Global Enterprises and its competitors. HealthCare Global Enterprises's current Buyback Yield % is -4.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthCare Global Enterprises stock overvalued right now?
Based on GuruFocus' analysis, HealthCare Global Enterprises (NSE:HCG) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹579.88, compared to a current price of ₹686.35 — trading 18.4% above its estimated fair value. The current Buyback Yield % is -4.51. HealthCare Global Enterprises' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For HealthCare Global Enterprises (NSE:HCG), the current Buyback Yield % is -4.51 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HealthCare Global Enterprises (NSE:HCG) Overvalued in 2026?
Based on GuruFocus' analysis, HealthCare Global Enterprises stock appears to be overvalued.
The current stock price of ₹686.35 is trading 18.4% above its estimated GF Value™ of ₹579.88.
GuruFocus considers HealthCare Global Enterprises to be Modestly Overvalued.
Key valuation signals for NSE:HCG:
Buyback Yield %: -4.51
GF Value™: ₹579.88 vs. price of ₹686.35 (18.4% above fair value)
No single metric tells the full story. See the NSE:HCG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HealthCare Global Enterprises Business Description
HealthCare Global Enterprises Ltd operates in oncology, providing comprehensive cancer diagnosis and treatment services including medical oncology, radiation therapy, and surgical oncology. It also offers fertility treatment services under the Milann brand, along with multi-specialty hospital care in key medical disciplines. The company's operations span many metropolitan and non-metro cities across India and extend internationally with cancer care centers in Africa. HCG generates revenue through patient services in oncology, fertility treatments, diagnostics, and multi-specialty hospital care, leveraging technology and a networked business model to deliver patient-centric healthcare.
83GF Score
Get the complete analysis for NSE:HCG
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HCG has been successfully added to your 
